²¹²Pb-DOTAM-GRPR1

Phase 1Small molecule

OOrano Med LLC

²¹²Pb-DOTAM-GRPR1 is one of 14 small molecule programs targeting Recurrent or Metastatic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent or MetastaticRecruiting

Recurrent or MetastaticPhase 1

Recruiting

Competition

Competitive Landscape

15 competitors in Recurrent or Metastatic

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

5 2

Lynparza

AstraZeneca

Phase 2

1 3

Paraplatin

AAvyxa

Phase 2

6 4

Taxotere

AAvyxa

Phase 2

1 5

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 6

Inlyta

PPrism Pharmaceuticals

Phase 2

1 7

FH-006

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 8

Sacituzumab Tirumotecan

Merck & Co.

Phase 2

1 9

SI-B001

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 10

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 1Recruiting

Recurrent or Metastatic

NCT05283330

Clinical

Trials by Indication[1]

Recurrent or Metastatic1 trial

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting·OOrano Med LLC·Phase 1·NCT05283330·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ²¹²Pb-DOTAM-GRPR1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ²¹²Pb-DOTAM-GRPR1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ²¹²Pb-DOTAM-GRPR1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orano Med LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOrano Med LLC

²¹²Pb-DOTAM-GRPR1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Recurrent or Metastatic1 trial

References

Drug Info

Quick Facts

Related News